Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)

Trial Profile

A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Peginterferon alfa-2b (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma; Renal cell carcinoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms KEYNOTE-029
  • Sponsors Merck Sharp & Dohme Corp.
  • Most Recent Events

    • 01 Jul 2021 Results (At data cutoff February 18, 2019; n=102 ) from cohort 1C, evaluating standard dose pembrolizumab with two other alternative ipilimumab regimens in advanced melanoma, published in the Clinical Cancer Research
    • 05 Apr 2021 Status changed from active, no longer recruiting to completed.
    • 15 Feb 2021 Planned End Date changed from 8 Feb 2021 to 11 Mar 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top